Jarvik Heart and Leviticus Cardio yesterday unveiled a new collaborative wirelessly-powered left ventricular assist device and touted its recent first-in-human use. An article on the new heart and its first implantation was recently published in the Journal for Heart and Lung Transplantation, the companies said. The device, dubbed the Fully Implanted Ventricular Assist Device (FIVAD), […]
Launchpad Medical has raised $8.5 million in a new round of equity financing, according to recently posted SEC filings. The Lowell, Mass.-based medtech company is developing the Tetranite injectable, synthetic adhesive solution intended for bone repair. Tetranite is bioresorbable and is designed to provide instant adhesive capabilities to treat fractured bone and to stabilize metal […]
Jarvik Heart said today that the FDA approved an investigational device exemption trial of its miniature left ventricular assist device in patients of less than 1 year of age to 10 years. The 88-patient study is designed to compare the Jarvik 15mm LVAD with Berlin Heart‘s Excor device as a bridge to transplant over 6 months. […]
Jarvik Heart said it won pre-market approval from the Japanese Pharmaceuticals & Medical Devices Agency for its Jarvik 2000 heart, a left ventricular-assist device.
New York-based Jarvik Heart said the device is the smallest LVAD approved for long-term use in Japan.
Updated: March 15, 2012 9:30 a.m.
MASSDEVICE ON CALL — Stable heart disease patients were no better off with a stent with less-costly drug therapy in a recent study comparing the 2 treatments. *
Implanting a stent to prop open blocked arteries represents a more costly alternative that failed to improve outcomes in stable patients, according to researchers from the Stony Brook University Medical Center in New York.